Oramed Pharmaceuticals (ORMP) Total Current Liabilities (2011 - 2026)

Oramed Pharmaceuticals has reported Total Current Liabilities for 16 years, with the latest figure at $10.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 92.33% year-over-year to $10.6 million; the trailing twelve-month figure through Mar 2026 stood at $10.6 million (up 92.33% YoY), and the FY2025 full-year result was $19.1 million, up 235.73% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $10.6 million, down from $19.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $78.2 million in Q3 2023, with the low at $1.1 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $15.0 million across 5 years, with a median of $6.1 million in 2025.
• Annual changes were most pronounced in 2023 — Total Current Liabilities surged 1098.08% — and 2024, when it slumped 93.25%.
• Oramed Pharmaceuticals' Total Current Liabilities stood at $5.7 million in 2022, then jumped by 826.11% to $53.2 million in 2023, then tumbled by 89.32% to $5.7 million in 2024, then surged by 235.73% to $19.1 million in 2025, then sank by 44.66% to $10.6 million in 2026.
• The last three Total Current Liabilities figures came in at $10.6 million (Q1 2026), $19.1 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.